Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
Australia Extends Fuel Sulphur Relaxation Amid Iran War Supply Disruptions 
Anthropic CEO Meets Trump Officials to Discuss Powerful New AI Model Mythos 
Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion 
VANCOUVER, British Columbia, March 02, 2017 -- Aquinox Pharmaceuticals, Inc. (“Aquinox”) (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology, will report its financial results for the year ending December 31, 2016 and will provide a general business update on Thursday, March 9, 2017 after U.S. financial markets close. Aquinox will host a conference call and live audio webcast on Thursday, March 9th, 2017 at 4:30 PM (ET) / 1:30 PM (PT).
Conference Call and Webcast Details:
Date: Thursday, March 9th, 2017
Time: 4:30 PM (ET) / 1:30 PM (PT)
Toll-free: (866) 357-7878
International: (315) 625-3088
Conference ID: 72144360
Webcast URL: http://edge.media-server.com/m/p/askid88w
The live webcast may be accessed through the "Events & Presentations" page in the "Investor Relations" section of the company's website at www.aqxpharma.com.
The archived webcast will also be available on Aquinox's website approximately two hours after the event and will be available for replay for at least 30 days after the event.
About Aquinox Pharmaceuticals, Inc.
Aquinox Pharmaceuticals, Inc. is a late clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. Our primary focus is anti-inflammatory product candidates targeting SH2-containing inositol-5'-phosphatase 1, or SHIP1, which is a key regulator of an important cellular signaling pathway in immune cells, known as the PI3K pathway. Aquinox's lead drug candidate, AQX-1125, is a small molecule activator of SHIP1 suitable for oral, once daily dosing. In September 2016, we began enrolling patients in a Phase 3 clinical trial of AQX-1125 in our lead indication, Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS). Other indications are under consideration for future investigation. Aquinox has a broad intellectual property portfolio and pipeline of preclinical drug candidates that activate SHIP1. For more information, please visit www.aqxpharma.com.
Investor Contact Info:
Brendan Payne
Associate Director, Investor Relations
Aquinox Pharmaceuticals, Inc.
604.901.3019
[email protected]
Gitanjali Ogawa
Vice President
The Trout Group
646-378-2949
[email protected]
